# A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)

> **NCT03894280** · PHASE1 · COMPLETED · sponsor: **Respirent Pharmaceuticals Co Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
- **DRUG:** SERETIDE DISKUS® 250/50 inhalation powder/GSK
- **OTHER:** Activated Charcoal suspension

## Key facts

- **NCT ID:** NCT03894280
- **Lead sponsor:** Respirent Pharmaceuticals Co Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-12
- **Primary completion:** 2019-04-09
- **Final completion:** 2019-05-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03894280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03894280, "A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT03894280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*